The current financial score of Maravai LifeSciences Holdings Inc is 7.60. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 51.44M, representing a year-over-year increase of 8.53%, while its net profit experienced a year-over-year increase of 68.64%.
The current valuation score of Maravai LifeSciences Holdings Inc is 9.27. Its current P/E ratio is -10.20, which is -618.37% below the recent high of 52.87 and -22.12% above the recent low of -12.46.
The current earnings forecast score of Maravai LifeSciences Holdings Inc is 7.56. The average price target is 7.42, with a high of 8.00 and a low of 6.50.
The current price momentum score of Maravai LifeSciences Holdings Inc is 5.26. Currently, the stock price is trading between the resistance level at 9.03 and the support level at 6.10, making it suitable for range-bound swing trading.
The current institutional shareholding score of Maravai LifeSciences Holdings Inc is 10.00. The latest institutional shareholding proportion is 95.39%, representing a quarter-over-quarter increase of 5.60%. The largest institutional shareholder is Chuck Royce, holding a total of 1.81M shares, representing 0.09% of shares outstanding, with 185.57% increase in holdings.
The current risk assessment score of Maravai LifeSciences Holdings Inc is 5.45. The company's beta value is 0.69. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.